RU-1205

Synthetic nonsteroidal estrogen

RU-1205
File:RU-1205.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

RU-1205 is a synthetic, nonsteroidal estrogen that belongs to the class of compounds known as stilbestrol derivatives. It was developed in the 1960s by the French pharmaceutical company Roussel Uclaf.

Chemical Structure and Properties

RU-1205 is chemically classified as a stilbestrol derivative, which is a group of synthetic compounds that mimic the structure and function of natural estrogens. The chemical structure of RU-1205 is characterized by the presence of a phenyl group and a hydroxyl group, which are essential for its estrogenic activity.

Error creating thumbnail:

Chemical structure of RU-1205

The molecular formula of RU-1205 is C₁₆H₁₆O₂, and it has a molecular weight of 240.30 g/mol. The compound is known for its high affinity for estrogen receptors, which allows it to exert potent estrogenic effects in the body.

Pharmacology

RU-1205 acts as an agonist of the estrogen receptor, which means it binds to and activates these receptors, mimicking the effects of endogenous estrogens such as estradiol. This activation leads to the transcription of estrogen-responsive genes, resulting in various physiological effects.

The compound has been studied for its potential use in hormone replacement therapy and other estrogen-related treatments. However, like many synthetic estrogens, RU-1205 may also have side effects, including an increased risk of thrombosis and breast cancer, which are common concerns with estrogen therapy.

Development and Research

RU-1205 was developed during a period of extensive research into synthetic estrogens, which were being explored for their potential therapeutic applications. Although RU-1205 showed promise in preclinical studies, it did not advance to widespread clinical use, possibly due to the emergence of other synthetic estrogens with more favorable safety profiles.

Research into RU-1205 has contributed to the understanding of estrogen receptor interactions and the development of other estrogenic compounds. The study of such compounds has been crucial in the development of selective estrogen receptor modulators (SERMs) and other targeted therapies.

Related Compounds

RU-1205 is related to other synthetic estrogens such as diethylstilbestrol (DES) and hexestrol. These compounds share similar structural features and pharmacological properties, although each has unique characteristics that influence their clinical use and safety profiles.

Related Pages

• Estrogen receptor
• Hormone replacement therapy
• Selective estrogen receptor modulator
• Diethylstilbestrol